Monthly Archives: January 2008

Consolidation Trends Within the Blossoming RegenMed Service Sector

The WuXi acquisition of Apptec (posted last week) is continuing the trend of consolidation in the cell manufacturing sector. It is similar to Lonza’s (a Swiss company) purchase of Cambrex’s biologics division in 2006, and GE’s purchase of Wave Biotech … Continue reading

Posted in Apptec, BD, Bioprocessing, Invitrogen, JNJ, Lonza, Manufacturing, Progenitor Cell Therapy, Regenerative Medicine, Stem Cells Inc, WuXi Pharmatech | 1 Comment

Biomimetics Therapeutics Expands into New Markets with Innovative GEM OS Combination Device

by Susan Hsiong, PhD Biomimetics Therapeutics, Inc. (Franklin, TN), a company which develops drug-device combination products for orthopedic applications, recently announced positive results from its Canadian clinical study evaluating its GEM OSĀ®1 Bone Graft for the open surgical treatment of … Continue reading

Posted in Biomaterials, biomimetics therapeutics, bone regeneration, combination products, Company Profiles, controlled release, Medtronic, Regenerative Medicine | Tagged , , , , , , , , | 3 Comments

Chinese CRO WuXi Pharmatech Acquires Apptec Laboratory Services

WuXi (pronounced Woo-See) Pharmatech, a contract research organization (CRO) based in China, announced the acquisition of MN-based Apptec Laboratory Services. WuXi acquired Apptec to gain an immediate US footprint, better access to the US market, and important biologics expertise to … Continue reading

Posted in Apptec, BD, Bioprocessing, business models, Company Profiles, Invitrogen, JNJ, Lonza, Manufacturing, Regenerative Medicine, WuXi Pharmatech | 1 Comment

Celgene Strengthens Adult Stem Cell Patent Estate

I have recently signed up for the StemCellPatents.com weekly newsletter, and it is great to keep updated on all the patents that get issued in regenerative medicine. In the most recent newletter, they reported on two patents that issued last … Continue reading

Posted in adult stem cell, Biomaterials, Celgene, Intellectual Property, placenta stem cells, Regenerative Medicine, stem cells | Tagged , , , , | 1 Comment

New Year’s Resolutions for the Regenerative Medicine Industry

With the New Year upon us, I thought it would be good to make a set of New Year’s Resolutions for the regenerative medicine industry. This set of resolutions is not company specific, but things that will be required to … Continue reading

Posted in business models, Innovation, Regenerative Medicine | Tagged , , , | 2 Comments